45 results on '"Turtle, Cameron J."'
Search Results
2. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
3. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
4. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
5. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
6. Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
7. T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
8. A stochastic framework for evaluating CAR T cell therapy efficacy and variability
9. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
10. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
11. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
12. Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy
13. Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL
14. Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study
15. Serial Stimulation of CAR-T Cells Manufactured from Different T Cell Subsets Reveals Distinct Patterns of Dysfunction That Are Dissociated from Immunophenotypic Exhaustion
16. Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy
17. High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL
18. Evidence generation and reproducibility in cell and gene therapy research: A call to action
19. Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry
20. Non-Responsiveness to Immediate Pre CAR-T Treatment Does Not Preclude Response to Axicabtagene Ciloleucel in Relapsed and Refractory Aggressive B Cell Lymphomas
21. Novel, Gene-Level Associations between the Microbiome and MAIT or Treg Reconstitution after Allogeneic HSCT
22. IL-15 Serum Concentrations and CD19 CAR T-Cell Therapy: Impact on Clinical Outcomes and In Vivo CAR T Cell Kinetics
23. Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
24. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
25. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
26. Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival
27. Clinical Outcomes of CLL Patients with Relapsed or Refractory Disease after CD19-Specific CAR-T Therapy
28. Factors Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
29. Building and Sailing the Ship Simultaneously: A Programmatic Ecosystem for Cellular Based Therapies
30. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
31. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
32. Reply
33. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
34. Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
35. Multivariate Analyses Indicate That the Cytokine Response to Lymphodepletion May be Better Associated Than Lymphodepletion Intensity with the Efficacy of CD19 CAR-T Cell Immunotherapy for Aggressive B-Cell Non-Hodgkin Lymphoma
36. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
37. Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation
38. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
39. HLA Engineering of Human Pluripotent Stem Cells
40. Engineered T cells for anti-cancer therapy
41. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy
42. A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic Chemotherapy
43. Adoptive transfer of virus-specific and tumor-specific T cell immunity
44. Clinical-scale elutriation as a means of enriching antigen-presenting cells and manipulating alloreactivity
45. Single step enrichment of blood dendritic cells by positive immunoselection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.